

Hemifacial Spasm Market Size is Projected to See a Notable Growth

Market Overview

According to a report published by Market Research Future (MRF), the global [hemifacial spasm market size](#) is projected to reach USD 3170 million by 2030 at a CAGR of 5.4% over the forecast period of 2022 to 2030.

Hemifacial spasm is a painless neurological disorder consisting of persistent or fleeting involuntary contractions or twitches of the muscles innervated by the touching of a blood vessel to a facial nerve, or due to a facial nerve injury, or in severe cases, a tumor.

The influential factors driving the growth of the global hemifacial spasm market is the improvement of the healthcare sector globally, owing to the developing economic conditions, government efforts such as favorable regulations and expenditure towards research and development for providing better healthcare facilities, and the growing awareness among consumers regarding healthcare.

Additionally, technological advancements in medical science have risen the chances of treatment for almost all disorders.

On the other hand, challenges faced by the global hemifacial spasm market are the cost of treatment, side effects of the botulinum toxin which is used during treatment, and the presence of counterfeit drugs or treatment methods.

Segmental Analysis

The global hemifacial spasm market is segmented on the basis of diagnosis, treatment, end user, and region.

Based on the diagnosis, the market has been segmented into magnetic resonance imaging (MRI), angiography (arteriography), computed tomography (CT or CAT scan), and others.

Based on treatment, the hemifacial spasm market has been segmented into medical treatment, surgical treatment, physical therapy, combinational therapy, transcutaneous electric nerve stimulation (TENS) therapy, and others. The medical treatment segment has been sub-segmented into Botulinum Neurotoxin (BoNT) injections, and pharmaceuticals. The surgical treatment is sub-segmented into microvascular decompression (MVD), and others.

Based on end-users, the market for hemifacial spasm has been segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.

Based on regions, the market has been segmented into the Americas, Europe, Asia Pacific, and the Middle East And Africa.

Key Players



global [hemifacial spasm market](#) players are US WorldMeds (U.S.), Abbott (U.S.), Cephalon Inc. (U.S.), Shire plc (U.S.), Stryker (U.S.), Sunovion Pharmaceuticals, Inc. (U.S.), Pfizer (U.S.), Revance Therapeutics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Valeant Pharmaceuticals International, Inc., (Canada), GlaxoSmithKline plc (UK), Merz Pharma GmbH and Co. KGaA (Germany), Sanofi S.A (France), UCB S.A. (Belgium), Ipsen Group (France), Novartis AG (Switzerland), Allergan, Inc. (Ireland), Roche (Switzerland), Medytox, Inc. (South Korea), and H.C. (U.S.).

